Roivant Sciences Ltd
F:87S
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
7.9
11.885
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Roivant Sciences Ltd
Roivant Sciences Ltd
Cash from Financing Activities
Roivant Sciences Ltd
Cash from Financing Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Roivant Sciences Ltd
F:87S
|
Cash from Financing Activities
$419.4m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
|
Cash from Financing Activities
$21.1m
|
CAGR 3-Years
149%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Autolus Therapeutics PLC
NASDAQ:AUTL
|
Cash from Financing Activities
-$883k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Cash from Financing Activities
$519.9m
|
CAGR 3-Years
58%
|
CAGR 5-Years
44%
|
CAGR 10-Years
N/A
|
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Cash from Financing Activities
£34.3m
|
CAGR 3-Years
-33%
|
CAGR 5-Years
221%
|
CAGR 10-Years
N/A
|
|
|
Genus PLC
LSE:GNS
|
Cash from Financing Activities
-£2.8m
|
CAGR 3-Years
42%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Roivant Sciences Ltd
Glance View
Roivant Sciences Ltd. is a dynamic biopharmaceutical company that has carved a unique niche in the pharmaceutical landscape by focusing on the efficient development of innovative therapies. Founded in 2014, Roivant operates on a model that leverages technology and data to accelerate drug discovery and commercialization, which allows it to bring treatments to market more swiftly than traditional pharmaceutical firms. With a roster of subsidiary companies, each specializing in different therapeutic areas, Roivant aims to tackle unmet medical needs, particularly in neuroscience, immunology, and rare diseases. This approach not only diversifies its portfolio but also enhances the potential for successful product launches, appealing to investors looking for promising biotech opportunities. At the heart of Roivant's strategy is its commitment to harnessing innovative technologies, including artificial intelligence and decentralized clinical trials, that streamline the drug development process. The company has established partnerships with leading research institutions and pharmaceutical giants, enhancing its credibility and expanding its reach. As Roivant progresses through clinical trials and advances its pipeline, investors are provided with unique opportunities to participate in groundbreaking treatments that could improve patient outcomes and generate significant returns. With its nimble structure, emphasis on collaboration, and pursuit of disruptive innovations, Roivant stands out as a compelling player in the evolving world of biopharmaceuticals, representing both promise and potential for those willing to engage with its journey.
See Also
What is Roivant Sciences Ltd's Cash from Financing Activities?
Cash from Financing Activities
419.4m
USD
Based on the financial report for Mar 31, 2024, Roivant Sciences Ltd's Cash from Financing Activities amounts to 419.4m USD.
What is Roivant Sciences Ltd's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 3Y
-3%
Over the last year, the Cash from Financing Activities growth was -16%. The average annual Cash from Financing Activities growth rates for Roivant Sciences Ltd have been -3% over the past three years .
You don't have any saved screeners yet
